Search Results

IDBS announced that it has entered into a partnership with Massachusetts-based PharmaEssentia Innovation Research Center on its Polar platform to help digitize data management and facilitate collaboration between the company’s global research and development teams.

DeepQure, a Seoul based medical device company with a novel, extravascular solution for renal denervation, announced initiation of its Early Feasibility Study for the HyperQure™ system following FDA IDE approval.

Venus Medtech, a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed innovative transcatheter pulmonic valve replacement system, VenusP-Valve, has completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine.

Kardium Inc. announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial for pulsatile intravascular lithotripsy (PIVL) therapy.

Establishment Labs Holdings Inc. noted the presentation today of an update on the Motiva US IDE Study.

IDBS has appointed Pietro Forgione as its new General Manager. Pietro has spent the last 16 years at IDBS with responsibilities for EMEA sales, Global Key Accounts, and most recently, as Vice President of Product, Strategy and Marketing.